Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10695MR)

This product GTTS-WQ10695MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALB&IL17A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized; Vicugna pacos (alpaca)
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3605
UniProt ID P02768; Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10695MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6956MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ7731MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ10777MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ6884MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ4779MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ9166MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ15201MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ15339MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW